Kornimate/medical-research-clean huggingface dataset:
comparison of different orthodontic aligner systems applied on single stage and three stage

Conditions: Tooth Crowding; Tooth; Lesion, White Spot Lesions

Summary: applying to the orthodontics department of the faculty of dentistry of erciyes university for orthodontic treatment, a periodontally healthy 16-26 year-old periodontally healthy, non-congenital or congenital anomaly in the craniofacial region; 25 patients with class 1 orthodontic malocclusion with moderate permeability will be included in the study. the patients will be divided into 2 groups, and the first group of 12 patients will have single-stage aligner; the second group of 13 patients is planned to apply 3-stage aligner.

it is planned to take lateral cephalometric radiography, panoramic radiography before and after the orthodontic treatment, and in addition to orthodontic model and photograph records before, during and after the treatment. patient comfort and satisfaction will be evaluated by applying questionnaires to patients before treatment, immediately after starting treatment, 2 days later, 1 week later, 1 month later, 1 week before and after the treatment, and the effects of 2 different treatment methods on the patients will be evaluated according to the data obtained. qlf recordings are also taken at the beginning of treatment and at 3-month intervals, and the effects of single plaque use and 3 different plaque use on white spot lesion formation will be evaluated. hays nance analysis will be used in the orthodontic models to determine the change in the amount of perplexity. in this way, tooth movement speeds can be determined. there are studies in the literature with single-stage transparent plates, but there are no studies with different-stage plates. in our study, which of the two different types of treatment is more comfortable on patients and affects the movement of teeth faster; in addition, the investigators plan to investigate which one has a low risk of white spot lesions on the teeth.

Eligibility criteria:
inclusion criteria: * no systemic disease * being healthy as periodontal. * no smoking. * no previous orthodontic treatment. * lack of congenital tooth deficiency * permanent dentition * class 1 malocclusion * no clefts * no extracted teeth exclusion criteria: * orthodontic treatment history * missing tooth * poor oral hygiene * lack of cooperation
effect of low-glycemic index mediterranean diet on ages

Conditions: Type 2 Diabetes; Insulin Resistance; Obesity; Cardiovascular Disease

Summary: advanced glycation end products (age) result from a chemical reaction between the carbonyl group of reducing sugar and the nucleophilic nh2 of a free amino acid or a protein; lysine and arginine being the main reactive amino acids on proteins. following this first step, a molecular rearrangement occurs, rearrangement of amadori resulting to the formation of maillard products.

specialized receptors (rage, galectin 3...) bind age. the binding to the receptor causes the formation of free radicals, which have a deleterious effect because they are powerful oxidizing agents, but also play the role of intracellular messenger, altering the cell functions. this role is especially true at the level of endothelial cells as the attachment of age to rage receptor causes an increase in vascular permeability. age binding to endothelium rage and to monocytes-macrophages, led to the production of cytokines, growth factors, to the expression of adhesion molecules, and the production of procoagulant activity. increased permeability, facilitation of leukocyte migration, the production of reactive oxygen species, cytokines and vegf suggest that the age could be an element of a cascade of reactions responsible for the diabetic angiopathy and vascular damages observed during aging and chronic renal failure. recently, it's been proposed that balanced diets can limit the deleterious effect of age. for these reasons, the interest in preventive approaches complementary or alternative to cholesterol reduction should be one of the main objectives of cardiovascular research in the years to come. already in the '70s the very low incidence of atherosclerotic diseases in mediterranean countries (greece and southern italy) and the importance of the "dietary factor" in such protection were noticed. diets for people in these countries are, among other components, very rich in oleic acid, the main constituent of olive oil, with about 29% of daily caloric intake derived from monounsaturated fatty acids. aim of this trial is to estimate the effect of a low glycemic index mediterranean diet on age products.

Eligibility criteria:
inclusion criteria: * subject enrolled in the nutriep cohort assembled in 2005-2007 exclusion criteria: * not enrolled in the nutriep cohort * pregnancy

Keywords: mediterranean diet low-glycemic index ages
a post market study on dorsal root ganglion (drg) stimulation in failed back surgery syndrome (fbss)

Conditions: Failed Back Surgery Syndrome

Summary: 18-smi-2013 is a post market, observational, questionnaire based study to assess the effectiveness of the commercially available axium neurostimulator in the management of chronic pain following lumbar discectomy (failed back surgery syndrome)


Eligibility criteria:
inclusion criteria: 1. subject is at least 18 years old 2. subject is able and willing to comply with the follow-up schedule and protocol 3. chronic pain following surgical lumbar discectomy for at least 6 months 4. failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and interventional pain procedures for chronic pain 5. minimum baseline pain rating of 60 mm on the visual analog scale in the subjects primary area of pain 6. subject is able to provide written informed consent exclusion criteria: 1. female subject of childbearing potential is pregnant/nursing or plans to become pregnant during the course of the study 2. escalating or changing pain condition within the past month as evidenced by investigator examination 3. subject has had corticosteroid therapy at an intended site of stimulation within the past 30 days 4. subject has had radiofrequency treatment of an intended target dorsal root ganglion within the past 3 months 5. subject currently has an active implantable device including implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump 6. subject is unable to operate the device 7. subjects with indwelling devices that may pose an increased risk of infection 8. subjects currently has an active infection 9. subject has participated in another clinical investigation within 30 days 10. subject has a coagulation disorder or uses anticoagulants that, in the opinion of the investigator, precludes participation 11. subject has been diagnosed with cancer in the past 2 years. 12. subject has an anatomical spinal abnormality which is anticipated to require further surgery
txa study in major burn surgery

Conditions: Tranexamic Acid; Burn; Major Surgery

Summary: major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. tranexamic acid (txa) is a medication that was first introduced in the 1960's as a treatment for heavy menstrual bleeding. over the past 20 years, it has been used and studied in patients undergoing open-heart surgery, liver transplantation, and urologic surgery. investigators believe tranexamic acid may possibly decrease bleeding related to major burn surgery, resulting in reduced blood loss, lower blood transfusion rates, and possibly decreased hospital costs related to your stay. in this study, prior to each surgical procedure to treat the participants burn injury, the participant will receive either the drug tranexamic acid or placebo. the placebo is a liquid that looks like the tranexamic acid medicine, but does not have any active ingredient in it. in this study, both the tranexamic acid and the placebo are considered research.

neither the participant nor the study doctor will choose what treatment the participant gets. the participant will have an equal chance of being given the tranexamic acid or the placebo. neither the participant nor the study doctor will know which treatment the participant is receiving. the participant will receive one 1 gram dose of either tranexamic acid or placebo immediately before surgery. the dose of tranexamic acid or placebo will be given in the participants vein over a 10-minute period. information from the participants medical record related to their surgery and recovery time in the hospital will be collected by medical staff assisting with this study and recorded on study forms. these study forms will be labeled with the participants study number instead of their name.

Eligibility criteria:
inclusion criteria: * subjects undergoing burn excision surgery for standard of care purposes (to include: greater than or equal to 350 cm2 of full thickness or deep partial thickness burns) * male or female \> 18 years of age * subject or subject's medical decision maker agrees to participate in this study and provides informed consent exclusion criteria: * subjects with a history of hypercoagulopathy, deep vein thrombosis (dvt), pulmonary embolism * baseline creatinine level greater than 2.83 mg/dl * subjects with known hypersensitivity to tranexamic acid * patients with acquired defective color vision * patients with subarachnoid hemorrhage * children * pregnant women * prisoners

Keywords: tranexamic acid burn surgery tangential excision
long-term observation of pap-therapy with telemonitoring: telemedicine registry telepap

Conditions: Obstructive Sleep Apnea; Central Sleep Apnea; Mixed Sleep Apnea

Summary: telemonitoring for positive airway pressure (pap) therapy might help to establish and maintain long-term therapy adherence and thus support the beneficial effects of pap therapy on long-term outcomes.

airway obstructions, airflow resistance by partial occlusion of the airways or central sleep-breathing disorders, where the respiratory effort is reduced or stops, cause a reduction in airflow and lead to arousals from sleep and disturbances in gas exchange during sleep. the negative consequences manifest in increases of blood pressure, higher workload for the heart and daytime sleepiness. pap (positive airway pressure) treats sleep-related breathing disorders. it applies pressure to nose and mouth to keep the airway from collapsing and provides pressure support to assist the respiratory muscles. the efficacy of the therapy is measured with apnoea- and hypopnoea-indices that count the total number of apnoeic events at night. to ensure an efficacious and efficient therapy, pressures have to be adjusted correctly and the patient needs to use pap regularly. telemonitoring is information and communication technology to exchange sleep data and to provide clinical guidance over distances. there is no defined spectrum of technology. it can comprise phone calls, video support or interaction programs via the internet. some studies point to advantages of telemonitoring in keeping compliance upright, increase usage hours and some also point to economic advantages. however, we do not have conclusive data from large trials with telemonitoring on the long-term that would show conclusive effects, be it from the side of a patient or from a cost and labour perspective of providers or the healthcare sector. still, there are uncertainties regarding data safety, reimbursement or connectivity of different systems. no long-term data of pap therapy under telemonitoring and its effect on compliance and therapy outcomes is available by now.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * new indication for a prescription of a telemonitoring (airviewtm)-capable resmed pap-device * consent to use the telemonitoring system airviewtm (resmed gmbh \& co kg) * signed informed consent exclusion criteria: - pregnant and breastfeeding persons
pilot study for the development of an activity and quality of life questionnaire for the follow-up of patients with non-dystrophic myotonia

Conditions: Non-Dystrophic Myotonia

Summary: non-dystrophic myotonias (mnd) are rare neuromuscular diseases caused by mutations in the voltage-dependent channels of skeletal muscles, resulting in delayed muscle relaxation after voluntary contraction. they include various conditions such as congenital myotonia, congenital paramyotonia and sodium channel myotonia. the main characteristic is myotonia, muscle stiffness accompanied by pain, fatigue and weakness. symptoms vary in intensity, and fluctuation complicates clinical assessment. until now, no validated scale to assess the severity of myotonia is the subject of a consensus among neurologists. it therefore seems necessary to establish a scale to simply and quickly assess the severity of myotonia to fill this need. the areas of this future scale were identified by the study coordinator based on existing questionnaires and scales. these areas have been validated by a scientific committee composed of expert neurologists. the main objective of the study is to validate the adequacy and formulation of the scale questions by involving 10 patients who will complete the questionnaire twice to assess its fidelity. at the end of the study, the committee will exclude inappropriate questions. the goal is to create a reliable scale to assess the severity of myotonia.


Eligibility criteria:
inclusion criteria: * male or female, over 18 years of age; * with genetically diagnosed non-dystrophic myotonia; * affiliated with a social security system; * able to read, understand and speak french * having expressed his non-opposition exclusion criteria: * subject participating in an interventional study with experimental drug or in the exclusion period of an interventional study; * pregnant or lactating women for women of childbearing age; * patient protected by law under guardianship or curators, or who cannot participate in a clinical study under article l. 1121-16 of the french public health code
using neuroimaging to early diagnose alzheimer's disease through hippocampal atrophy assessment

Conditions: Alzheimer&#39;s Disease; Hippocampus; Brain Atrophy; Magnetic Resonance Imaging; Leukoaraiosis; Neurodegenerative Diseases; Cortical and Subcortical Atrophy

Summary: this study aims to better understand alzheimer's disease by looking at brain scans, specifically mri images, to detect early signs of brain changes linked to the disease. researchers are focusing on the hippocampus, a part of the brain that shrinks in people with alzheimer's. the study will also explore other brain changes that often happen alongside hippocampal shrinkage. by analyzing these brain images, the study hopes to find ways to diagnose alzheimer's earlier and more accurately using advanced imaging techniques.


Eligibility criteria:
inclusion criteria: * patients who underwent a brain mri (3d t1 bravo and cube flair sequences) between january 2018 and june 2022. * diagnosis of alzheimer's disease (for the alzheimer group). * no neurological disease for control group participants. * complete clinical and biological assessments available. * quality imaging without motion artifacts. exclusion criteria: * incomplete clinical or radiological data. * poor image quality (e.g., motion artifacts). * presence of other neurodegenerative or psychiatric disorders.
environmental design for behavioral regulation in people with dementia

Conditions: Alzheimer Disease

Summary: individuals with dementia present with changes in behaviors throughout the continuum of cognitive decline. environmental features may be influential in behavioral regulation. the purpose of this study is to assess the feasibility of environmental design protocols in older adults with dementia and their caregivers. thirty subjects with moderate to severe alzheimer's disease as primary dementia type, and their caregivers, will be randomly assigned to one of three arms: standard care; standard environmental design protocol; or personalized environmental design protocol.


Eligibility criteria:
inclusion criteria: * men or women aged 21-90, inclusive. * living at home in the community with one primary caregiver. * diagnosis of alzheimer's disease as primary dementia type of moderate to severe stages * stable medical condition for one month prior to screening visit * stable medications for 4 weeks prior to screening visit * caregiver report of challenges related to behaviors within 4 weeks of study enrollment * caregiver willing to participant throughout duration of study exclusion criteria: * unstable medical conditions for 3 months prior to screening * wheelchair or bed bound. * residence in skilled nursing facility or facility-based care. * skin lesions or skin abnormalities throughout upper extremities.

Keywords: environment occupational therapy
study evaluating emergency-use tigecycline in subjects with resistant pathogens.

Conditions: Bacterial Infections

Summary: the purpose of this study is to provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations. the secondary objective is to evaluate the safety and efficacy of tigecycline in the treatment of patients with selected serious infections where other treatment has not been successful.


Eligibility criteria:
inclusion criteria: * male or female subjects, greater than 8 years of age and a weight of more than 35 kilograms. * patients with current bacterial infections who have not responded to other available appropriate antibiotic therapies. * patient must give informed consent. exclusion criteria: * patients with an expected survival of less than 2 weeks. * patients who have been designated as "do not resuscitate". * known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents. * pregnant women or nursing mothers.

Keywords: bacterial infections
everolimus for the treatment of uveitis unresponsive to cyclosporine a

Conditions: Uveitis

Summary: study efficacy of everolimus on course of uveitis: * obtain quiescence of inflammation after start of treatment * duration to obtain quiescence of inflammation * number of patients with quiescence of inflammation

occurence of new complications from uveitis * course of visual acuity (logmar): percentage of patients with visual loss of 10 or more numbers on etdrs as compared to baseline * change of recurrence rate as compared to time before everolimus treatment * occurence of recurrence after obtaining remission with everolimus treatment * duration to occurence of recurrence o number of patients with recurrence * corticosparing effect from everolimus * number of patients without topical corticosteroids; number of patients with reduced topical corticosteroids (\<3x/daily) * number of patients without systemic corticosteroids; number of patients with reduced systemic corticosteroids (\<10mg/daily) * efficacy of uveitis within 12 months * maintenance of remission after withdrawel of everolimus treatment at 12 months o course of cystoid macula edema (fla, oct)

Eligibility criteria:
inclusion criteria: * endogenous intermediate or posterior uveitis * no quiesence in previous 3 months under systemic and topical steroids or systemic cyclosporine a * indication for steroid sparing therapy * uveitis related vision threating complications * negative pregnancy test * effective contraception exclusion criteria: ophthalmic parameters: * silicone oil in anterior chamber of both eyes para- or intraocular corticosteroid injections within previous 8 weeks * opacities of optic media that obscure visualization of anterior or posterior eye segments general parameters: * requirement for combined immunosuppression for systemic immune-mediated disease contraindication against everolimus or cyclosporine a * positive tuberculine test (gt 10 * currently immunosuppressive therapy with immunosuppressive drug other than cyclosporine * poor compliance * known intolerance to medication

Keywords: endogoneous posterior intermediate
spleen preserving surgery for splenic hydatidosis: a cohort study on short and long-term outcomes

Conditions: Spleen-Preserving Surgery; Echinococcus Granulosus Infection; Hydatid Disease; Minimally Invasive Surgery

Summary: this retrospective cohort study examines the effectiveness of minimally invasive spleen-preserving surgeries compared to total splenectomy for treating primary splenic hydatidosis in jordan. covering 18 patients from january 2015 to june 2021, the research highlights similar recurrence rates between both surgical approaches, emphasizing the benefits of spleen preservation in maintaining immune function and reducing septic risks, particularly in pediatric patients.

the study delves into a detailed analysis of 18 cases of primary splenic hydatid cysts treated through spleen-preserving surgeries-laparoscopic partial splenectomy, cystectomy, and cyst deroofing-augmented by albendazole therapy. it presents a comprehensive comparison based on patient demographics, symptoms, surgical details, and outcomes, including complications and recurrence rates. findings reveal no significant statistical difference in recurrence rates between spleen-preserving methods and total splenectomy, suggesting the viability of less invasive approaches for managing this condition effectively while preserving spleen functionality and minimizing post-operative complications. the study underlines the need for individualized treatment plans and further research with larger cohorts.

Eligibility criteria:
inclusion criteria: * adult patients (age 14 years or older). * diagnosed exclusively with primary, non-recurrent splenic hydatid cysts. exclusion criteria: * children under 14 years of age. * patients in late pregnancy. * individuals with recurrent cysts. * cases with extra-splenic involvement. * patients with less than two years of postoperative follow-up.

Keywords: spleen-preserving surgery primary splenic hydatid cyst hydatid disease minimally invasive surgery echinococcus granulosus recurrence